Announcements Trials
Browse Landscape

Status

Approved for marketing 2Available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 123Observational 22Expanded_access 3

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Genitourinary 1

Conditions

Gastrointestinal Neoplasms 2Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Sunitinib × Clear all
NCT06948955 2026-05-08

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Available
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT00094029 2012-03-09

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Pfizer

Approved for marketing
Gastrointestinal

Gastrointestinal Neoplasms

NCT00130897 2012-03-09

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Pfizer

Approved for marketing
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡